PT814838E - Sistema de apresentacao de antigenio e activacao de celulas t - Google Patents

Sistema de apresentacao de antigenio e activacao de celulas t

Info

Publication number
PT814838E
PT814838E PT96909631T PT96909631T PT814838E PT 814838 E PT814838 E PT 814838E PT 96909631 T PT96909631 T PT 96909631T PT 96909631 T PT96909631 T PT 96909631T PT 814838 E PT814838 E PT 814838E
Authority
PT
Portugal
Prior art keywords
cell activation
presentation system
antigen presentation
molecules
sup
Prior art date
Application number
PT96909631T
Other languages
English (en)
Inventor
Michael Jackson
Zeling Cai
Jonathan Sprent
Anders Brunmark
Per A Petterson
Alain M D Luxembourg
Didier Jean Leturcq
Ann M Moriarty
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of PT814838E publication Critical patent/PT814838E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0601—Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/50—Coculture with; Conditioned medium produced by invertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18822—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/75—Vector systems having a special element relevant for transcription from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT96909631T 1995-03-08 1996-03-08 Sistema de apresentacao de antigenio e activacao de celulas t PT814838E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40033895A 1995-03-08 1995-03-08

Publications (1)

Publication Number Publication Date
PT814838E true PT814838E (pt) 2003-09-30

Family

ID=23583206

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96909631T PT814838E (pt) 1995-03-08 1996-03-08 Sistema de apresentacao de antigenio e activacao de celulas t

Country Status (11)

Country Link
US (10) US6461867B1 (pt)
EP (1) EP0814838B1 (pt)
JP (2) JP3926842B2 (pt)
AT (1) ATE240119T1 (pt)
AU (1) AU720201B2 (pt)
CA (1) CA2214649C (pt)
DE (1) DE69628154T2 (pt)
DK (1) DK0814838T3 (pt)
ES (1) ES2201177T3 (pt)
PT (1) PT814838E (pt)
WO (1) WO1996027392A1 (pt)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0937251T3 (da) 1996-09-06 2007-02-19 Ortho Mcneil Pharm Inc Oprensning af antigenspecifikke T-celler
DK1123086T3 (da) * 1998-10-20 2010-06-14 Androclus Technologies S R L I Kunstige antigen-specifikke celler og tilhørende fremgangsmåder
US20030166057A1 (en) * 1999-12-17 2003-09-04 Hildebrand William H. Method and apparatus for the production of soluble MHC antigens and uses thereof
US7521202B2 (en) * 1999-12-17 2009-04-21 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of soluble MHC antigens and uses thereof
US20060276629A9 (en) * 1999-12-17 2006-12-07 Hildebrand William H Purification and characterization of soluble human HLA proteins
US20060035338A1 (en) * 1999-12-17 2006-02-16 Pure Protein Llc Method and apparatus for the production of soluble MHC antigens and uses thereof
AUPQ755300A0 (en) * 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
DE60138922D1 (de) * 2000-10-10 2009-07-16 Univ Oklahoma Vergleichende ligandenabbildung aus mhc-positiven zellen
US20070099182A1 (en) * 2000-10-10 2007-05-03 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
US20020122820A1 (en) * 2001-01-16 2002-09-05 Hildebrand William H. Soluble MHC artificial antigen presenting cells
EP2848255B1 (en) 2001-02-20 2017-08-23 Janssen Pharmaceuticals, Inc. Artificial Drosophila antigen presenting cell for preparing CD8 cell suspension for use in the treatment of cancer
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
IL157492A0 (en) * 2001-02-21 2004-03-28 Univ Oklahoma Hla ligand database utilizing predictive algorithms and methods of making and using same
AU2002252253A1 (en) * 2001-03-09 2002-09-24 Rico Buchli Epitope testing using hla
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
ATE438710T1 (de) 2001-05-15 2009-08-15 Ortho Mcneil Janssen Pharm Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
WO2003024312A2 (en) * 2001-09-17 2003-03-27 Valeocyte Therapies Llc Cell therapy system
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
US7955845B2 (en) 2001-11-20 2011-06-07 Dana Farber Cancer Institute, Inc. Modified antigen-presenting cells
US20040126829A1 (en) * 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
WO2003057852A2 (en) * 2001-12-18 2003-07-17 Hildebrand William H Purification and characterization of hla proteins
AU2003235652A1 (en) * 2002-01-15 2003-07-30 Advanced Cell Technology, Inc. Cloning b and t lymphocytes
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
DE10231655A1 (de) * 2002-07-12 2004-02-26 Blasticon Biotechnologische Forschung Gmbh Transplantat-Akzeptanz induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung
AU2003270876A1 (en) * 2002-09-24 2004-04-19 Rico Buchli Anti-hla assay and methods
US20040072262A1 (en) * 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
US20070178532A1 (en) * 2003-03-24 2007-08-02 The Gov.Of The Us As Represented By The Secretary Identification, quantification, and characterization of t cells and t cell antigens
US20040248205A1 (en) * 2003-04-16 2004-12-09 Stern Lawrence J. Major histocompatibility complex (MHC)-peptide arrays
KR20060040671A (ko) * 2003-07-11 2006-05-10 블라스티콘 바이오테크놀로지셰 포르슝 게엠베하 단구성 기원의 자기 유래 자가 관용성 유도 세포 및약제학적 제제에 있어서의 이의 용도
JP2007511760A (ja) * 2003-11-03 2007-05-10 ベックマン コールター インコーポレーティッド Ｍｈｃ結合ペプチドを検出するための溶液ベースの方法
US20050130897A1 (en) * 2003-12-11 2005-06-16 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
EP2573166B1 (en) 2004-02-26 2016-05-11 Immunovative Therapies, Ltd. Methods for preparing T-cells for cell therapy
US7592431B2 (en) * 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
HUE035726T2 (en) 2004-03-01 2018-05-28 Immunovative Therapies Ltd Cell therapy formulation method and composition
JP2007536522A (ja) * 2004-05-07 2007-12-13 ベックマン コールター インコーポレーティッド Ｃｔｌの媒介による抗原提示細胞の溶解を検出するためのｍｈｃ架橋系
US7678379B2 (en) * 2004-06-17 2010-03-16 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
WO2006081620A1 (en) * 2005-02-02 2006-08-10 Newsouth Innovations Pty Limited Cd4+ cd25+ t-cells activated to a specific antigen
EP1712615A1 (en) * 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
ES2368152T3 (es) * 2005-07-01 2011-11-14 Txcell S.A. Obtención de células tr1 específicas de antígenos de los alimentos o de autoantígenos a partir de una población de leucocitos o pbmc.
ES2579762T3 (es) 2006-03-01 2016-08-16 Janssen Pharmaceutica N.V. Tratamiento del cáncer combinando agente linfo - reductor con CLTs y citoquinas
US8569059B2 (en) 2006-08-02 2013-10-29 Newsouth Innovations Pty Limited Method of identifying CD4+ CD25+ T-cells activated to an antigen which express CD8
CA2665568C (en) * 2006-10-04 2018-01-09 Janssen Pharmaceutica, N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
WO2009139921A2 (en) * 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
AU2010329805B2 (en) 2009-12-11 2016-07-14 Proyecto De Biomedicina Cima S.L. New conjugates and compositions for immunotherapy and anti-tumoral treatment
WO2012151279A2 (en) 2011-05-03 2012-11-08 Michael Har-Noy Induction of il-12 using immunotherapy
WO2012151266A1 (en) 2011-05-03 2012-11-08 Michael Har-Noy Methods for handling biological drugs containing living cells
US8834889B2 (en) * 2011-08-29 2014-09-16 National Tsing Hua University Antigen presenting composition and use thereof
CN107058101B (zh) 2011-10-17 2021-06-01 麻省理工学院 细胞内传递
CA2858115A1 (en) 2011-12-09 2013-06-13 The Johns Hopkins University Artificial antigen presenting cells having a defined and dynamic shape
EP2841563B1 (en) 2012-04-24 2019-06-12 Dan S. Kaufman Method for developing natural killer cells from stem cells
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
EP3033184B1 (en) 2013-08-16 2021-03-31 Massachusetts Institute of Technology Selective delivery of material to cells
US20160320408A1 (en) 2013-12-19 2016-11-03 Opexa Therapeutics, Inc. Methods of t cell epitope profiling, making t cell compositions, and treating diseases
EP3656864A1 (en) 2014-02-14 2020-05-27 Board of Regents, The University of Texas System Chimeric antigen receptors and methods of making
KR20160145802A (ko) 2014-04-23 2016-12-20 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법
EP3134515B1 (en) 2014-04-24 2019-03-27 Board of Regents, The University of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
JP7523203B2 (ja) 2014-10-31 2024-07-26 マサチューセッツ インスティテュート オブ テクノロジー 生体分子の免疫細胞への送達
AU2015343013B2 (en) 2014-11-05 2020-07-16 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
CA2964783C (en) 2014-11-05 2024-01-23 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
WO2016077761A1 (en) 2014-11-14 2016-05-19 Massachusetts Institute Of Technology Disruption and field enabled delivery of compounds and compositions into cells
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
CN107250373A (zh) 2015-01-12 2017-10-13 麻省理工学院 通过微流体递送实现的基因编辑
SG10201912910PA (en) 2015-07-09 2020-02-27 Massachusetts Inst Technology Delivery of materials to anucleate cells
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
US11059879B2 (en) 2015-10-27 2021-07-13 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
SG11201810640RA (en) 2016-06-08 2018-12-28 Intrexon Corp Cd33 specific chimeric antigen receptors
US20240018268A1 (en) 2016-07-29 2024-01-18 Juno Therapeutics, Inc. Anti-idiotypic antibodies against anti-cd19 antibodies
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
EP3538112B1 (en) 2016-11-09 2026-02-25 Musc Foundation for Research Development Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
KR20190102259A (ko) 2017-01-10 2019-09-03 인트렉손 코포레이션 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절
WO2018148671A1 (en) 2017-02-12 2018-08-16 Neon Therapeutics, Inc. Hla-based methods and compositions and uses thereof
WO2018195175A1 (en) 2017-04-18 2018-10-25 FUJIFILM Cellular Dynamics, Inc. Antigen-specific immune effector cells
EP3635132A4 (en) 2017-06-07 2021-05-26 Intrexon Corporation EXPRESSION OF NOVEL CELL MARKERS
TWI832820B (zh) * 2017-07-21 2024-02-21 美商伯克利之光生命科技公司 抗原呈現合成表面、共價功能化表面、經活化之t細胞及其用途
CN119930795A (zh) 2017-10-12 2025-05-06 得克萨斯大学体系董事会 用于免疫疗法的t细胞受体
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
WO2020055246A1 (en) 2018-09-11 2020-03-19 Rijksuniversiteit Groningen Biological nanopores having tunable pore diameters and uses thereof as analytical tools
CA3112813A1 (en) * 2018-09-21 2020-03-26 Berkeley Lights, Inc. Functionalized well plate, methods of preparation and use thereof
WO2020069377A1 (en) * 2018-09-27 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of using lysine deacetylase (kdac) inhibition to generate antigen specific memory t cell responses for durable immunotherapy
WO2020113029A2 (en) 2018-11-28 2020-06-04 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
MX2021006393A (es) 2018-11-29 2021-10-13 Univ Texas Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
AU2019404547B2 (en) 2018-12-21 2025-01-30 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
US11246906B2 (en) 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
AU2020311877B2 (en) 2019-07-05 2024-01-04 Case Western Reserve University Priming media and methods for stem cell culture and therapy
KR20220095228A (ko) 2019-11-06 2022-07-06 베이롤 칼리지 오브 메드신 암의 t 세포 치료를 위한 세포독성 효과기 기억 t 세포를 생산하는 방법
US20230079539A1 (en) 2020-02-10 2023-03-16 Board Of Regents, The University Of Texas System Methods for rapid cloning and expression of hla class i cells
KR20220147106A (ko) 2020-02-28 2022-11-02 도쿠리츠다이가쿠호징 가나자와다이가쿠 항원 제시 세포 외 소포, 그것을 포함하는 조성물, 및 그들을 제조하기 위한 방법
KR20230016178A (ko) 2020-04-15 2023-02-01 엘커메스 파마 아일랜드 리미티드 혈관신생 억제제와 조합된 면역자극제
IL298558A (en) 2020-05-27 2023-01-01 Antion Biosciences Sa Adapter molecules redirect CAR T cells to the antigen of interest
CN113913458A (zh) * 2020-07-09 2022-01-11 杭州优凯瑞医药科技有限公司 非病毒方法制备稳定高表达嵌合受体的nk细胞
US12275766B2 (en) 2020-12-23 2025-04-15 Janssen Biotech, Inc. Neoantigen peptide mimics
WO2022165426A2 (en) 2021-02-01 2022-08-04 The Board Of Trustees Of The Leland Stanford Junior University Determination and uses of cd8+ t cell epitopes
WO2022187280A1 (en) 2021-03-01 2022-09-09 Dana-Farber Cancer Institute, Inc. Personalized redirection and reprogramming of t cells for precise targeting of tumors
EP4514382A1 (en) 2022-04-28 2025-03-05 Musc Foundation for Research Development Chimeric antigen receptor modified regulatory t cells for treating cancer
IL320502A (en) 2022-10-28 2025-06-01 Univ Groningen Nanopore-based protein efflux

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5580562A (en) * 1990-03-14 1996-12-03 Board Of Regents The University Of Texas System Preparations and uses thereof for immunosuppression
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5314813A (en) * 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
US5731160A (en) * 1992-05-26 1998-03-24 Rijksuniversiteit Leiden Induction of antigen specific T-lymphocyte responses by stimulation with peptide loaded MHC class I molecules on antigen processing defective mammalian cell lines
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5763585A (en) * 1993-10-13 1998-06-09 Anergen, Inc. Method of making MHC-peptide complexes using metal chelate affinity chromatography
US6090587A (en) * 1993-10-25 2000-07-18 Corixa Corporation Prokaryotic expression of MHC proteins
US5595881A (en) * 1994-08-09 1997-01-21 Anergen, Inc. Method for the detection of antigen presenting cells
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof

Also Published As

Publication number Publication date
AU5306096A (en) 1996-09-23
ATE240119T1 (de) 2003-05-15
EP0814838B1 (en) 2003-05-14
EP0814838A1 (en) 1998-01-07
US20030138946A1 (en) 2003-07-24
JP4629650B2 (ja) 2011-02-09
CA2214649C (en) 2007-06-12
JP3926842B2 (ja) 2007-06-06
JP2007161719A (ja) 2007-06-28
US6225042B1 (en) 2001-05-01
US6362001B1 (en) 2002-03-26
JPH11501516A (ja) 1999-02-09
ES2201177T3 (es) 2004-03-16
US20050152916A1 (en) 2005-07-14
DE69628154T2 (de) 2004-03-18
EP0814838A4 (en) 2000-04-12
US20030072796A1 (en) 2003-04-17
DK0814838T3 (da) 2003-09-15
CA2214649A1 (en) 1996-09-12
WO1996027392A1 (en) 1996-09-12
US6828150B2 (en) 2004-12-07
US20030077318A1 (en) 2003-04-24
US6251627B1 (en) 2001-06-26
US20030077708A1 (en) 2003-04-24
DE69628154D1 (de) 2003-06-18
US6255073B1 (en) 2001-07-03
US6461867B1 (en) 2002-10-08
AU720201B2 (en) 2000-05-25

Similar Documents

Publication Publication Date Title
PT814838E (pt) Sistema de apresentacao de antigenio e activacao de celulas t
ATE347588T1 (de) Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten
Pichler et al. T cells as antigen-presenting cells
AU7979094A (en) Methods and compositions for microencapsulation of adjuvants
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
DK1634949T3 (da) Fremgangsmåde til at generere aktiverede T-celler og antigen-inkuberede antigen-præsenterende celler
EP1203817A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
HUP9802538A2 (hu) Vektorok és eljárások helyspecifikus rekombináció előidézésére
BR9806764A (pt) Moléculas mutantes ctla4 solúveis e usos das mesmas.
CA2176713A1 (en) Amphiphilic Imidazolinium Derivatives
Montes et al. Calcium responses elicited in human T cells and dendritic cells by cell–cell interaction and soluble ligands
IT1245417B (it) Composizione di innesco/detonatore adatta per l'impiego in scodellini di rame
IL92629A0 (en) Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
MX9802730A (es) Agonistas receptores hematopoyeticos multifuncionales.
NL194083B (nl) Verenigbare polymeermengsels van twee verschillende polymethacrylaten respectievelijk polyacrylaten, alsmede de toepassing daarvan.
IL110585A0 (en) Tripeptides, their preparation and pharmaceutical compositions containing them
MX9202643A (es) Peptidos utiles en la regulacion de los sistemas inmunologico y nervioso.
DE69612738D1 (de) Anzeigevorrichtung
Fleischer et al. Molecular associations required for signalling via dipeptidyl peptidase IV (CD26)
SI0969865T1 (sl) Sistem za prikaz mhc razred ii antigenov in postopek za aktiviranje cd4? + t celic
DE69835615D1 (de) Induzierte zelluläre immunitität durch aktivierung der th1 und unterdrückung der th2 antwort durch macrophhagen
EP1032418A4 (en) COMPACT REPLICONS OF THE EPSTEIN-BARR VIRUS
AU1799097A (en) Presentation of antigen, introduced into the cells by stimulation of macropinocytosis
Ellsberg Word of mouth.
Posnansky African art in Japan.